- Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
- Some insiders were making return trips to the buy window last week.
- Insider buying was also happening in the wake of recent earnings reports.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason: they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets or the markets are near all-time highs.
Note that with earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week.
In the latest of a number of purchases stretching back to late May, a Cricut Inc CRCT 10% owner picked up over 1.09 million more shares at prices ranging from $25.84 to $28.99 apiece. These latest purchases added up to almost $29.62 million. Note that some insiders sold more than 50,000 shares altogether late in the week as well.
The B Riley Financial Inc RILY board chair, Bryant Riley, purchased 145,000 shares, and two other insiders also picked up 15,000 shares, last week. At $59.23 to $64.18 apiece, the cost for those shares totaled around $10.06 million altogether. Note that Riley also bought more than 24,000 shares in the previous week.
The indirect purchase of almost 114,400 Kodiak Sciences Inc KOD shares by a 10% owner at $84.69 to $89.73 apiece totaled around $10 million. That same owner bought over 107,000 shares in the previous week, and the more than 13.2 million share stake compares to the 45 million or so shares outstanding.
Late in the week, a director at Morphic Holding Inc MORF indirectly acquired more than 74,900 of its shares. At prices ranging from $54.42 to $57.00 per share, the transactions added up to more than $4.21 million. Earlier this month, the biopharmaceutical company posted top-line results that fell short of estimates.
Biomea Fusion Inc BMEA CEO Andrew Butler has acquired more than 204,400 shares for $10.76 to $17.00 apiece. That cost him around $3.3 million. This biopharmaceutical company also recently posted a net loss, and the stock closed on Friday at $11.17 a share. That is down about 18% from a month ago.
Health care management company Apollo Medical Holdings Inc AMEH had a 10% owner step up to the buy window last week. That owner acquired 40,000 shares from a company director for $73.67 apiece. That totaled almost $2.95 million, and it lifted the owner's stake to more than 10.9 million shares. Around 44 million shares are outstanding.
A Myovant Sciences Ltd MYOV 10% owner indirectly purchased some shares of this biopharma company last week. At per-share prices of $20.46 to $22.08, the more than 138,600 shares acquired cost that owner nearly $2.9 million and lifted the stake to over 48.7 million shares.
Chinook Therapeutics Inc KDNY saw CEO Eric Dobmeier and another director add 218,500 shares altogether during the week. These transactions totaled more than $2.61 million, at share prices ranging from $11.45 to $12.00. The shares were last seen trading above that range, at $12.76 apiece.
Software company Applovin Corp APP saw its chief financial officer double a stake by purchasing 25,000 shares for about $1.5 million. The share price ranged from $59.98 to $60.00. Note that other insiders sold 66,500 shares last week, after a rally in the shares due to the prior week's better than expected earnings report.
See also: 4 Stocks Insiders Are Selling
Note that some smaller amount of insider buying at Bright Health Group Inc BHG, Cirrus Logic, Inc. CRUS, Compass Diversified Holdings CODI, FireEye Inc FEYE, Herbalife Nutrition Ltd HFL, Ralph Lauren Corp RL, Six Flags Entertainment Corp LPX and SoFi Technologies Inc SOFI was reported in the past week as well.
At the time of this writing, the author had no position in the mentioned equities.
Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.